For China [email protected] Vienna, we have invited Key Opinion Leaders in pharma industry, pioneers in cross-border transactions, and experts in regulatory, legal and financial topics to share their experiences and expertise to all participants who want to explore opportunities with China’s emerging healthcare market.

We are bringing together 100+ Chinese biotech and pharma executives and investors interested in life science industry. After registration, you can login in our partnering system to schedule 1-to-1 meetings with our speakers for potential collaboration opportunities. Click here to see more attending speakers.

Register Now


Dr. Jun Bao has over 20 years of combined business and R&D experiences. He is highly experienced in the field of new drug R&D, tech transfer, licensing and business development, M&A, venture investment, company start-up and operation. He currently serves as President & CEO of Impact Therapeutics.
Jun Bao
President & CEO
Impact Therapeutics
Dr. Du has previously worked at US FDA for almost 7 years and reviewed more than 100 INDs and NDAs while in the Division of Pulmonary, Allergy and Rheumatology Products, and later in the Division of Oncology Products.
Tao (Tom) Du
Chief Consultant
Humphries Pharmaceutical Consulting
Dr. Du has helped more than 20 Chinese drug companies to submit ANDA or IND and initiate clinical trials for the development of herbal, biological, generic, and new chemical drugs in the United States.
Dr. Dang is responsible for all BD and external collaborations globally including in-license, out-license and setting strategies for drug discovery and external collaborations. He also has more than 20-years of experience as a manager of drug discovery programs spanning early to late stages; led programs that advanced multiple compounds into human clinical trials.
Qun (Max) Dang
Vice President, Global Head of BD and External Innovation, PR&D
Qilu Pharmaceutical
Dianna has extensive expertise in corporate development, private equity, and financial modeling. Her previous experience included BCG, McKinsey’s, Baxter, Boehringer Ingelheim, Fidelity Asia Growth Partners, and Fountainvest.
Jing (Dianna) Qian
Pivotal bioVenture Partners
Dr. Xu had thirteen plus years of research experience in oncology and CNS areas when he worked in BMS and Wyeth.  He also worked in many different CRO companies such as WuxiApptec, Crownbio and HD Biosciences as Senior director, executive director and vice president responsible for in US and global business development activities.
Jun (John) Xu
CEO and cofounder
Jemincare Therapeutics